SC 13G/A | 2024-02-14 | Avoro Capital Advisors LLC | Apellis Pharmaceuticals, Inc. | 13,411,111 | 9.9% | EDGAR |
SC 13G/A | 2024-02-14 | EcoR1 Capital, LLC | Apellis Pharmaceuticals, Inc. | 11,173,068 | 9.4% | EDGAR |
SC 13G | 2024-02-14 | T. Rowe Price Investment Management, Inc. | Apellis Pharmaceuticals, Inc. | 6,303,584 | 5.3% | EDGAR |
SC 13G/A | 2024-02-13 | VANGUARD GROUP INC | Apellis Pharmaceuticals, Inc. | 9,555,678 | 8.1% | EDGAR |
SC 13G/A | 2024-02-08 | WELLINGTON MANAGEMENT GROUP LLP | Apellis Pharmaceuticals, Inc. | 16,477,850 | 13.9% | EDGAR |
SC 13G/A | 2023-09-08 | WELLINGTON MANAGEMENT GROUP LLP | Apellis Pharmaceuticals, Inc. | 14,770,859 | 12.6% | EDGAR |
SC 13G | 2023-07-18 | EcoR1 Capital, LLC | Apellis Pharmaceuticals, Inc. | 6,307,547 | 5.4% | EDGAR |
SC 13G/A | 2023-07-07 | BlackRock Inc. | Apellis Pharmaceuticals, Inc. | 5,747,184 | 4.9% | EDGAR |
SC 13G/A | 2023-02-14 | PRICE T ROWE ASSOCIATES INC /MD/ | Apellis Pharmaceuticals, Inc. | 2,749,542 | 2.5% | EDGAR |
SC 13G/A | 2023-02-14 | Avoro Capital Advisors LLC | Apellis Pharmaceuticals, Inc. | 10,625,000 | 9.6% | EDGAR |
SC 13G | 2023-02-14 | T. Rowe Price Investment Management, Inc. | Apellis Pharmaceuticals, Inc. | 5,842,660 | 5.3% | EDGAR |
SC 13G/A | 2023-02-09 | VANGUARD GROUP INC | Apellis Pharmaceuticals, Inc. | 9,212,491 | 8.3% | EDGAR |
SC 13G/A | 2023-02-06 | WELLINGTON MANAGEMENT GROUP LLP | Apellis Pharmaceuticals, Inc. | 8,820,398 | 8.0% | EDGAR |
SC 13G/A | 2023-02-01 | BlackRock Inc. | Apellis Pharmaceuticals, Inc. | 7,704,194 | 7.0% | EDGAR |
SC 13G/A | 2022-02-14 | HHLR ADVISORS, LTD. | Apellis Pharmaceuticals, Inc. | - | 0.0% | EDGAR |
SC 13G/A | 2022-02-14 | Morningside Venture Investments Ltd | Apellis Pharmaceuticals, Inc. | 12,806,342 | 13.2% | EDGAR |
SC 13G | 2022-02-14 | PRICE T ROWE ASSOCIATES INC /MD/ | Apellis Pharmaceuticals, Inc. | 5,307,486 | 5.4% | EDGAR |
SC 13G | 2022-02-11 | Avoro Capital Advisors LLC | Apellis Pharmaceuticals, Inc. | 8,555,555 | 8.9% | EDGAR |
SC 13G/A | 2022-02-09 | VANGUARD GROUP INC | Apellis Pharmaceuticals, Inc. | 7,917,099 | 8.1% | EDGAR |
SC 13G/A | 2022-02-04 | WELLINGTON MANAGEMENT GROUP LLP | Apellis Pharmaceuticals, Inc. | 12,478,253 | 12.8% | EDGAR |